Congenital Hyperinsulinism Diagnosis and Management @checkrare
Congenital Hyperinsulinism Diagnosis and Management  @checkrare
Uploaded July 2026 | Updated November 2026, 2 days ago
Kristen Rohli, PhD, Associate Director of Research at Congenital Hyperinsulinism International, discusses congenital hyperinsulinism (HI) diagnosis and management.

Congenital HI is a condition caused by abnormally high levels of insulin, a hormone that helps control blood sugar levels. People with this condition have frequent episodes of low blood sugar (hypoglycemia). In infants and young children, these episodes are characterized by lethargy, irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma.

Early symptoms of congenital HI can be challenging to recognize because they often mimic normal behaviors in babies such as excessive crying and eating or generally feeling displeased or uncomfortable. Other, more severe symptoms such as seizures and blue skin, may prompt more tests to be run. These babies often present with high insulin and low glucose in lab tests. Ms. Rohli highlights that about 60% of patients are diagnosed within the first year of life.

The only FDA approved medication for congenital HI is diazoxide, a nondiuretic benzothiadiazine that primarily acts as an ATP-sensitive potassium channel opener. However, Ms. Rohli explains that around 50% of patients do not respond to this medication. Other medications, such as somatostatin analogs octreotide and lanreotide, are used off-label. There are also currently many investigational treatments going through the clinical trial pipeline.

Congenital Hyperinsulinism International provides support, research, and awareness for patients, caregivers, and families. Clinicians can access international guidelines for diagnosis and treatment and families can view a translation of those guidelines into lay terms and images. Additionally, the organization works to connect families with each other and with a global patient registry. Family conferences are held twice a year where patients and families can meet each other and connect with top researchers. The next conference will be held in Marseille, France in September 2026.

CHAPTERS
Introduction 00:00
Congenital HI Overview 00:12
Symptoms and Diagnosis 00:38
Current Management 2:48
Congenital Hyperinsulinism International 3:29
Congenital Hyperinsulinism Diagnosis and ManagementResults from the CALIBRATE Clinical Trial in Patients With Autosomal Dominant Hypocalcemia Type 1Decoding Delays, Connecting the Care: The Challenge of Diagnosing Rare Endocrine DisordersRare Endocrine Exchange: Diagnosing Rare Endocrine DisordersAntiphospholipid Syndrome and PregnantASCO 2026: MajesTEC-9 Clinical Trial ResultsTaletrectinib for ROS1-Positive Non-Small Cell Lung CancerBreakthrough Therapy Designation to Cimzia for Antiphospholipid SyndromeASCO 2026: CARTITUDE-4 Cytogenetic Subgroup AnalysisDermiselagon Development for EPP and XLPFDA Approves New Therapies for MPS IIIA and SMABreakthrough Therapy Designation to Cimzia for Pregnancy Complications in Antiphospholipid Syndrome
CheckRare |

Congenital Hyperinsulinism Diagnosis and Management

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER